Lidoderm Patch

Lidoderm Patch

 Due to safety concerns regarding the entire COX-II inhibitor class in the fall of 2004, the sponsor of the study, Endo Pharmaceuticals Inc., voluntarily elected to prematurely halt the study prior to reaching the original enrollment target. However an analysis of data after six weeks of treatment showed that of the patients treated in the Lidoderm group (N=56), 54% experienced a 30% or greater improvement in average daily pain intensity; (studies have reported that 30% or greater reductions in pain intensity are clinically meaningful to pain patients). In the Celebrex group (N=63), 62% experienced a 30% or greater improvement in average daily pain intensity. In addition, clinically meaningful reductions in pain were noted in both treatment groups at week 12.

Lidoderm Patch

Lidoderm Patch

Lidoderm Patch

Lidoderm Patch

Lidoderm Patch

Lidoderm Patch

Lidoderm Patch

Lidoderm Patch

Lidoderm Patch